ARIA
Library/metabolic/Retatrutide

Retatrutide

Not FDA Approved✓ WADA Permitted
metabolic•clinicalTriple receptor agonist

Triple agonist at GLP-1, GIP, and glucagon receptors. Most advanced obesity peptide in clinical trials — up to 24% weight loss in Phase 2. Developed by Eli Lilly as the successor to tirzepatide. Activates GLP-1 for appetite suppression, GIP for metabolic enhancement, and glucagon receptor for increased energy expenditure.

Confidence
92%
Half-Life ~48 hours
Cost ~$1800/mo
Quick Reference
Routesubcutaneous
MechanismActivates GLP-1 receptor for appetite suppression, GIP receptor for metabolic en...
Reviewed2026-06-08

Mechanism of Action

Activates GLP-1 receptor for appetite suppression, GIP receptor for metabolic enhancement, and glucagon receptor for increased energy expenditure. Triple agonism creates synergistic metabolic effects.

Dosing Protocol

Phase 2: 4-8mg weekly for 24 weeks, titrating from 1mg. Phase 3 ongoing.

Adverse Effects

None reported in Phase 2 beyond expected class effectsNausea (35%)Vomiting (15%)Diarrhea (20%)Injection site reactions

Contraindications

  • Pregnancy
  • History of medullary thyroid carcinoma
  • Multiple endocrine neoplasia syndrome type 2
  • Pancreatitis history

Storage

Requires refrigeration 2-8°C